Jhaveri Kenar D, Bensink Mark E, Bunke Martin, Briggs Jonathon A, Cork David M W, Jeyabalan Anushya
Division of Kidney Diseases and Hypertension, Glomerular Center at Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 100 Community Drive, Great Neck, NY, 11021, USA.
Travere Therapeutics, Inc., San Diego, CA, USA.
Pharmacoecon Open. 2023 Sep;7(5):709-722. doi: 10.1007/s41669-023-00415-0. Epub 2023 Apr 27.
Immunoglobulin A nephropathy (IgAN) is a progressive inflammatory kidney disease requiring long-term treatment to reduce the risk of progression to kidney failure. Here, we present two systematic literature reviews (SLRs) to identify and summarize literature reporting the humanistic and economic burden of IgAN.
Electronic literature databases (Ovid Embase, PubMed, and Cochrane) were searched for relevant literature on 29 November 2021, supplemented with gray literature searches. Studies reporting any health-related quality of life (HRQoL) or health state utility outcomes in IgAN patients were included in the humanistic impact SLR, and studies reporting the costs and healthcare resource utilization associated with or economic models of IgAN disease management were included in the economic burden SLR. Narrative synthesis was used to discuss the heterogeneous studies included in the SLRs. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Cochrane guidelines were followed, and all included studies were assessed for risk of bias using the Center for Evidence-Based Management tool for Critical Appraisal of a Survey or the Drummond Checklist.
A total of 876 and 1122 references were identified from electronic and gray literature searches for humanistic and economic burden, respectively. Three studies reporting humanistic impact and five studies reporting economic burden met criteria for inclusion in these SLRs. The included humanistic studies reported patient preferences in the USA and China, HRQoL for patients with IgAN in Poland, and impact of exercise on HRQoL for patients with IgAN in China. The five economic studies reported costs of IgAN treatment in Canada, Italy, and China, along with two economic models from Japan.
Current literature suggests IgAN is associated with substantial humanistic and economic burdens. However, these SLRs demonstrate the paucity of research conducted to specifically describe the humanistic or economic burden of IgAN and highlight the need for further research.
免疫球蛋白A肾病(IgAN)是一种进行性炎症性肾病,需要长期治疗以降低进展为肾衰竭的风险。在此,我们进行两项系统文献综述(SLR),以识别和总结报告IgAN人文和经济负担的文献。
于2021年11月29日在电子文献数据库(Ovid Embase、PubMed和Cochrane)中检索相关文献,并辅以灰色文献检索。报告IgAN患者任何与健康相关的生活质量(HRQoL)或健康状态效用结果的研究纳入人文影响SLR,报告与IgAN疾病管理相关的成本和医疗资源利用或经济模型的研究纳入经济负担SLR。采用叙述性综合方法讨论SLR中纳入的异质性研究。遵循系统评价和Meta分析的首选报告项目(PRISMA)和Cochrane指南,并使用循证管理中心的调查批判性评价工具或Drummond清单对所有纳入研究进行偏倚风险评估。
分别从电子和灰色文献检索中识别出876篇和1122篇关于人文和经济负担的参考文献。三项报告人文影响的研究和五项报告经济负担的研究符合纳入这些SLR的标准。纳入的人文研究报告了美国和中国患者的偏好、波兰IgAN患者的HRQoL以及中国运动对IgAN患者HRQoL的影响。五项经济研究报告了加拿大、意大利和中国IgAN的治疗成本,以及来自日本的两个经济模型。
当前文献表明IgAN与巨大的人文和经济负担相关。然而,这些SLR表明专门描述IgAN人文或经济负担的研究很少,并强调了进一步研究的必要性。